Silence Therapeutics News

Buy Rating on Silence Therapeutics: Positive Phase 2 Data and Potential for Blockbuster Revenues

TipRanks59minutes ago

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading

European equities traded in the US as American depositary receipts were trending modestly higher late Friday morning, rising 0.29% to 1,426.43 on the S&P Europe Select ADR Index. The index is set to c

MT NewswiresMay 17 23:06

Chardan Capital: Maintains Silence Therapeutics (SLN.US) rating, adjusted from buy to buy rating, and adjusted target price from $42.00 to $42.00.

Chardan Capital: Maintains Silence Therapeutics (SLN.US) rating, adjusted from buy to buy rating, and adjusted target price from $42.00 to $42.00.

Zhitong FinanceMay 17 20:50

Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $42 Price Target

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics with a Buy and maintains $42 price target.

Analyst UpgradesMay 17 20:50

Silence Therapeutics (SLN.US): The 2024 Q1 financial report achieved revenue of US$15.734 million, previous value of US$13.815 million; earnings per share were -0.05 USD, prior value of -0.12 USD.

Silence Therapeutics (SLN.US): The 2024 Q1 financial report achieved revenue of US$15.734 million, previous value of US$13.815 million; earnings per share were -0.05 USD, prior value of -0.12 USD.

Zhitong FinanceMay 17 05:50

Silence Therapeutics Posts Reduced Q1 Losses

TipRanksMay 17 03:27

6-K: Report of foreign private issuer (related to financial reporting)

SEC announcementMay 17 02:26 · Announcements

European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading

European equities traded in the US as American depositary receipts were trending moderately lower late Thursday morning, declining 0.61% to 1,426.72 on the S&P Europe Select ADR Index. From continenta

MT NewswiresMay 16 23:04

Silence Therapeutics Q1 Collaboration Revenue £12.4M, Up £1M YoY; Cash Position £152.8M

Silence Therapeutics Q1 Collaboration Revenue £12.4M, Up £1M YoY; Cash Position £152.8M

BenzingaMay 16 20:42

Silence Therapeutics 1Q Rev GBP12.4M >SLN

Silence Therapeutics 1Q Rev GBP12.4M >SLN

Dow JonesMay 16 20:31

Press Release: Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress LONDON--(BUSINESS WIRE)--May 16, 2024-- Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a

Dow JonesMay 16 20:30

European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading

European equities traded in the US as American depositary receipts were trending slightly higher Wednesday morning, rising 0.10% to 1,427.23 on the S&P Europe Select ADR Index. From continental Europe

MT NewswiresMay 15 23:09

European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher

European equities traded in the US as American depositary receipts kicked off the week higher in Monday morning, rising 0.62% to 1,421.16 on the S&P Europe Select ADR Index. From continental Europe, t

MT NewswiresMay 13 23:12

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

European equities traded in the US as American depositary receipts rose late Thursday morning, gaining 0.35% to 1,403.4 on the S&P Europe Select ADR Index. From continental Europe, the gainers were le

MT NewswiresMay 9 23:03

Silence Therapeutics Files to Sell 5.71M American Depositary Shares for Holders

Seeking AlphaMay 8 05:26

Silence Therapeutics Announces Board Change

TipRanksMay 2 05:28

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered

BusinesswireApr 30 20:30

Silence Therapeutics Announces Retirement of Alistair Gray From Board of Directors

Silence Therapeutics plc (NASDAQ:SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered

BusinesswireApr 29 20:30

Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock

7 analysts have expressed a variety of opinions on Silence Therapeutics (NASDAQ:SLN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below summarizes their

BenzingaApr 23 02:00

Silence Therapeutics Is Maintained at Overweight by Morgan Stanley

Silence Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow JonesApr 23 01:39